This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Universal, off‑the‑shelf CAR‑T cell therapies using gene‑edited donor T cells are beginning ...
Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...
This story is part one in a four-part series about cell therapy created by the Fierce Biotech team. Gabrielle Masson, Helen Floersh, James Waldron and Max Bayer contributed reporting to this series.
With the FDA approval of lifileucel, a cell product consisting of unmodified but in vitro expanded tumor-infiltrating lymphocytes, in short TIL, for the treatment of patients with refractory ...
This story is part 2 in a four-part series about cell therapy created by the Fierce Biotech team. Part 1 is available here, part 3 is here and the final installment is here. Gabrielle Masson, Helen ...
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Scientists push CAR T cell therapy beyond blood cancers, unlocking potential for targeting solid tumors with enhanced delivery, resilience, and precision in the face of tough obstacles. Study: Beyond ...
The immune system is made up of different types of cells, which have different roles in protecting the body from infection. One type of immune cell called a B cell creates antibodies that attack ...
Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...
SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results